Background: The KRAS oncogene has a high prevalence in solid malignancies. Targeting
KRAS and inappropriate activation of the MAPK pathway with novel drugs is of interest. This …

Dysregulation of Ras and Rho family small GTPases drives the invasion and metastasis of
multiple cancers. For their biological functions, these GTPases require proper subcellular …

Farnesyl transferase inhibitors: the successes and surprises of a new class of potential cancer
chemotherapeutics Page 1 JANICE E Buss AND JAMES C MARSTERS, JR MINIREVIEW …

The physiological effects of a variety of N6‐substituted adenine and adenosine derivatives
called cytokinins have been documented in plants, but information on their occurrence and …

The development of farnesyltransferase inhibitors, a novel approach to non-cytotoxic
anticancer therapy, has been an active area of research over the past decade. Compounds …

Oncogenic ras mutations and aberrant Ras function are important in many human tumors, so
blocking the activity of oncogenic Ras has been a significant priority in recent drug discovery …

The demonstration that Ras requires prenylation for its cancer-causing activity led several
groups of investigators to an intense search for farnesyltransferase and …

TLN-4601 is a structurally novel farnesylated dibenzodiazepinone discovered through
DECIPHER, Thallion's proprietary drug discovery platform. The compound was shown to …

Protein farnesyltransferase (FTase), the enzyme responsible for protein farnesylation, has
become a key target for the rational design of cancer chemotherapeutic agents. Herein it is …

Dysregulation of isoprenoid biosynthesis is implicated in numerous biochemical disorders
that play a role in the onset and/or progression of age-related diseases, such as …